Public Health Vaccines
Privately-held biotechnology company based in Cambridge, MA focused on development of recombinant viral-vector vaccines and medical countermeasures for emerging infectious diseases. The organization advances vaccine candidates from preclinical work through clinical testing, performs technology transfer and manufacturing scale-up in collaboration with government and manufacturing partners, and manages government-funded development programs.
Industries
Nr. of Employees
small (1-50)
Public Health Vaccines
Products
PHV01 — Marburg virus vaccine candidate
Live, attenuated rVSV-vector vaccine candidate expressing Marburg virus glycoprotein, developed as a single-dose vaccine and advanced into clinical testing under government funding and tech-transfer programs.
PHV02 — Nipah virus vaccine candidate
Live, attenuated rVSV-vector vaccine candidate expressing Nipah virus glycoprotein; started Phase 1 clinical testing to evaluate safety and immunogenicity and funded through Phase 2 development by a philanthropic partnership.
PHV03 — Sudan ebolavirus vaccine candidate
rVSV-based vaccine candidate targeting Sudan ebolavirus leveraging the same vector platform technology and development approach used for other filovirus candidates.
PHV04 — Bundibugyo ebolavirus vaccine candidate
Planned rVSV-based vaccine candidate targeting Bundibugyo ebolavirus; development activities described as forthcoming.
Marburg vaccine candidate (PHV01)
A vaccine candidate developed by Public Health Vaccines for Marburg virus, leveraging the recombinant vesicular stomatitis virus (rVSV) vector platform, intended for use in Africa through a partnership with Institut Pasteur de Dakar.
rVSV-SUDV vaccine candidate
A single-dose vaccine against Marburg Virus leveraging the recombinant vesicular stomatitis virus (rVSV) vector platform, designed for rapid onset of protection and effective pre- and post-exposure prophylaxis.
PHV01 — Marburg virus vaccine candidate
Live, attenuated rVSV-vector vaccine candidate expressing Marburg virus glycoprotein, developed as a single-dose vaccine and advanced into clinical testing under government funding and tech-transfer programs.
PHV02 — Nipah virus vaccine candidate
Live, attenuated rVSV-vector vaccine candidate expressing Nipah virus glycoprotein; started Phase 1 clinical testing to evaluate safety and immunogenicity and funded through Phase 2 development by a philanthropic partnership.
PHV03 — Sudan ebolavirus vaccine candidate
rVSV-based vaccine candidate targeting Sudan ebolavirus leveraging the same vector platform technology and development approach used for other filovirus candidates.
PHV04 — Bundibugyo ebolavirus vaccine candidate
Planned rVSV-based vaccine candidate targeting Bundibugyo ebolavirus; development activities described as forthcoming.
Marburg vaccine candidate (PHV01)
A vaccine candidate developed by Public Health Vaccines for Marburg virus, leveraging the recombinant vesicular stomatitis virus (rVSV) vector platform, intended for use in Africa through a partnership with Institut Pasteur de Dakar.
rVSV-SUDV vaccine candidate
A single-dose vaccine against Marburg Virus leveraging the recombinant vesicular stomatitis virus (rVSV) vector platform, designed for rapid onset of protection and effective pre- and post-exposure prophylaxis.
Services
Transfer of vaccine manufacturing processes (bulk drug substance and finished drug product) to contract manufacturing sites to establish domestic Phase 2-scale production readiness and enable rapid scale-up.
Management and execution of advanced development programs funded by government and philanthropic organizations, coordinating technical, regulatory, and manufacturing activities.
Transfer of vaccine manufacturing processes (bulk drug substance and finished drug product) to contract manufacturing sites to establish domestic Phase 2-scale production readiness and enable rapid scale-up.
Management and execution of advanced development programs funded by government and philanthropic organizations, coordinating technical, regulatory, and manufacturing activities.
Expertise Areas
- Viral-vector vaccine development
- Clinical trial management (Phase 1–2)
- CMC and bioprocess development
- Technology transfer and manufacturing scale-up
Key Technologies
- Recombinant vesicular stomatitis virus (rVSV) vector platform
- Live-attenuated viral vector vaccines
- Upstream cell culture and fermentation
- Downstream purification processes
News & Updates
Contract to transfer production and testing of PHV01 to U.S.-based CGMP manufacturing sites to bolster domestic live viral vaccine production capacity.
Additional option under BARDA contract to advance vaccine candidates against Sudan ebolavirus and Bundibugyo ebolavirus, with funding to support development and initiation of new programs.
Technology transfer and licensing arrangement enabling PHV's Marburg vaccine candidate to be produced at a regional Vaccine Research Centre to improve access in Africa.
Start of Phase 1 trial to evaluate safety and immunogenicity of a single-dose rVSV-based Nipah vaccine candidate.
Initial BARDA contract and subsequent options to advance an rVSV-based Marburg vaccine candidate through advanced development and clinical testing.
Partnering agreement with CEPI providing funding to advance a single-dose rVSV-based Nipah vaccine candidate through Phase 2 and to establish an investigational stockpile.
Contract to transfer production and testing of PHV01 to U.S.-based CGMP manufacturing sites to bolster domestic live viral vaccine production capacity.
Additional option under BARDA contract to advance vaccine candidates against Sudan ebolavirus and Bundibugyo ebolavirus, with funding to support development and initiation of new programs.
Technology transfer and licensing arrangement enabling PHV's Marburg vaccine candidate to be produced at a regional Vaccine Research Centre to improve access in Africa.
Start of Phase 1 trial to evaluate safety and immunogenicity of a single-dose rVSV-based Nipah vaccine candidate.
Initial BARDA contract and subsequent options to advance an rVSV-based Marburg vaccine candidate through advanced development and clinical testing.
Partnering agreement with CEPI providing funding to advance a single-dose rVSV-based Nipah vaccine candidate through Phase 2 and to establish an investigational stockpile.